CDK1 and hepatocellular carcinoma: The downregulation of CDK1 as a consequence of exposure to the HSP90 inhibitors has been reported in different studies, such as by ganetespib in mantle cell lymphoma [43], tanespimycin in colon cancer [44], or by 17DMAG, a semi-synthetic derivative of geldanamycin in hepatocellular carcinoma [45].